Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLEARED
NCT06463457Phase 2Active, not recruiting
- Start
- Dec 2024
- Primary completion
- Nov 2028
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of tissue-plasminogen activator, darolutamide in prostate cancer (PCa). Started Dec 2024; status: active, not recruiting.
02
Drugs
tissue-plasminogen activatordarolutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06463457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06463457.